In 2018, pharmaceutical companies AstraZeneca and Eli Lilly each spent about a quarter of their prescription drug revenue on research and development. The companies are predicted to spend roughly two percent less of their revenue share on R&D in 2024.
Global R&D spending
In 2018, the pharmaceutical industry spent just under 180 billion U.S. dollars on research and development, which is an increase of over 10 billion compared to the previous year. By 2024, expenditures are expected to reach a total of over 210 billion U.S. dollars. Some 15 thousand prescription drugs were in the 2018 R&D pipeline, a global number that has been growing with each consecutive year. The drug count has doubled since 2006 and is set to increase even further in the future.
AstraZeneca
AstraZeneca is a British-Swedish multinational pharmaceutical company, based in Cambridge, United Kingdom. The company’s top product in 2018 was Symbicort, which is used for controlling and preventing symptoms of asthma. The product generated close to 2.6 billion U.S. dollars in revenue that year. Revenue earned through Symbicort has decreased each year since 2015.
Top 10 pharmaceutical companies based on R&D spending as revenue share in 2018 and 2024*
* R&D spending as a share of total prescription revenue. The statistic includes only the companies with the highest amount of R&D spending dollars.
** Forecast.
Profit from additional features by authenticating your Admin account
Please authenticate by going to "My account" → "Administration".
Then you will be able to mark statistics as favourites and use personal statistics alerts.
This feature is limited to our corporate solutions.
Please contact us to get started with full access to dossiers, forecasts, studies and international data.
Corporate Account
Statista Accounts:
Access All Statistics. Starting from $468 / Year
Basic Account
Get to know the platform
You only have access to basic statistics.
This statistic is not included in your account.
Single Account
Your perfect start with Statista
Instant access to 1m statistics
Download in XLS, PDF & PNG format
Detailed references
$59$39 / Month *
in the first 12 months
Corporate Account
Full access
Corporate solution including all features.
* All products require an annual contract; Prices do not include sales tax.
Statistics on "Pharmaceutical research and development"
Statista Accounts:
Access All Statistics. Starting from $468 / Year
Learn more about how Statista can support your business.
Evaluate. (June 4, 2019). Top 10 pharmaceutical companies based on R&D spending as revenue share in 2018 and 2024* [Graph]. In Statista. Retrieved May 31, 2020, from https://www.statista.com/statistics/309471/randd-spending-share-of-top-pharmaceutical-companies/
Evaluate. "Top 10 pharmaceutical companies based on R&D spending as revenue share in 2018 and 2024*." Chart. June 4, 2019. Statista. Accessed May 31, 2020. https://www.statista.com/statistics/309471/randd-spending-share-of-top-pharmaceutical-companies/
Evaluate. (2019). Top 10 pharmaceutical companies based on R&D spending as revenue share in 2018 and 2024*. Statista. Statista Inc.. Accessed: May 31, 2020. https://www.statista.com/statistics/309471/randd-spending-share-of-top-pharmaceutical-companies/
Evaluate. "Top 10 Pharmaceutical Companies Based on R&d Spending as Revenue Share in 2018 and 2024*." Statista, Statista Inc., 4 Jun 2019, https://www.statista.com/statistics/309471/randd-spending-share-of-top-pharmaceutical-companies/
Evaluate, Top 10 pharmaceutical companies based on R&D spending as revenue share in 2018 and 2024* Statista, https://www.statista.com/statistics/309471/randd-spending-share-of-top-pharmaceutical-companies/ (last visited May 31, 2020)
We use cookies to personalize contents and ads, offer social media features, and analyze access to our website. In your browser settings you can configure or disable this, respectively, and can delete any already placed cookies. For details, please see your browser’s Help section (by pressing F1). Please see our privacy statement for details about how we use data.
